Abstract:Safe delivery of mRNA to the brain will revolutionize the treatment of brain tumors. While lipid nanoparticles (LNPs) are clinically most advanced non-viral delivery vehicles for therapeutic mRNA, LNP-mediated mRNA delivery to the brain remains challenging. We hypothesized that rationally designed LNPs based on extracellular vesicle mimicry would enable efficient delivery of RNA therapeutics to brain cells without undue toxicity. We engineered LNPs consisting of four components similar to the formulation used in the mRNA COVID-19 vaccines (Moderna and Pfizer-BioNTech): ionizable lipid, cholesterol, helper lipid and polyethylene glycol (PEG)-lipid. We screened ten classes of helper lipids based on lipids enriched in extracellular vesicles to engineer biomimetic LNPs and tested their GFP mRNA delivery efficacy in SIM-A9 mouse microglia cell line. Several unique LNP formulations with potent delivery efficacy (>90% cells transfected) and stable GFP expression kinetics (5 days) were identified. LNP formulations with high transfection efficacy were then tested in vivo for luciferase mRNA delivery via intrathecal injection in C57BL/6 mice. Luciferase expression in vivo confirmed widespread mRNA delivery in the brain. We then tested Cre recombinase mRNA delivery in Ai9 mouse to identify LNP-targeted cells via flow cytometry and histology. Flow cytometry and expansion microscopy confirmed Cre recombinase mRNA delivery to a variety of brain cells, including microglia (75-90%), neurons (31-40%), neural stem cells (39-62%), oligodendrocytes (70-90%), and astrocytes (44-76%). LNPs were further evaluated for Cas9 mRNA and CD81 sgRNA delivery in C57BL/6 mouse brains to assess brain-targeted gene editing. Sanger sequencing showed that CRISPR-Cas9 editing was successful in ~40% of cells in the mouse brain. In summary, we engineered extracellular vesicle-based LNP library that can deliver RNA therapeutics to a variety of brain cells in vivo. With further development, this technology could potentially enable genetic and epigenetic therapies targeting drivers of brain tumors.

Lipid Nanoparticles Deliver mRNA to the Brain after an Intracerebral Injection

Intranasal Delivery and Transfection of mRNA Therapeutics in the Brain Using Cationic Liposomes.

In Vivo Introduction of mRNA Encapsulated in Lipid Nanoparticles to Brain Neuronal Cells and Astrocytes via Intracerebroventricular Administration

Ddel-01. Engineering Mrna Therapies For Brain Tumors

Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease

Brain gene therapy with Trojan horse lipid nanoparticles

Lipid nanoparticle-mediated drug delivery to the brain

A lipid nanoparticle-based oligodendrocyte-specific mRNA therapy

Branched‐Tail Lipid Nanoparticles for Intravenous mRNA Delivery to Lung Immune, Endothelial, and Alveolar Cells in Mice

One‐Component Cationic Lipids for Systemic Mrna Delivery to Splenic T Cells

Tetrahydropyrimidine Ionizable Lipids for Efficient mRNA Delivery

Intracellular Delivery of mRNA for Cell-Selective CRISPR/Cas9 Genome Editing using Lipid Nanoparticles

Targeting lipid nanoparticles to the blood-brain barrier to ameliorate acute ischemic stroke

Lung-Specific mRNA Delivery Enabled by Sulfonium Lipid Nanoparticles

Widespread Gene Editing in the Brain via In Utero Delivery of mRNA Using Acid-Degradable Lipid Nanoparticles

Silicon Ether Ionizable Lipids Enable Potent mRNA Lipid Nanoparticles with Rapid Tissue Clearance

Recent Advances in Lipid Nanoparticles for Delivery of mRNA

The Future of Tissue-Targeted Lipid Nanoparticle-Mediated Nucleic Acid Delivery

An overview of lipid constituents in lipid nanoparticle mRNA delivery systems

A scalable and robust cationic lipid/polymer hybrid nanoparticle platform for mRNA delivery

Lipid nanoparticle (LNP) mediated mRNA delivery in cardiovascular diseases: Advances in genome editing and CAR T cell therapy